Oct 31st Sandoz announced that the FDA has approved its adalimumab biosimilar named Hyrimoz (adalimumab-adaz) with indications for RA, JIA, PsA, AS, Crohns, ulcerative colitis and plaque psoriasis. https://t.co/9gH3X51GQj